For those of you who were unable to participate in our second quarter results conference call yesterday, you can now download the complete transcript, podcast, and presentation here.
As always, get in touch with me if you have any questions, and thanks again for checking in.
Friday, July 30, 2010
Thursday, July 29, 2010
Safeguard Scientifics' Aggregate Partner Company Revenue Up 47 Percent; Increases 2010 Guidance to be Between $325 Million and $350 Million
This morning, we announced that aggregate partner company revenue for the three months ended June 30, 2010 was $91.6 million, up 47 percent from $62.3 million for the same partner companies in the same period of 2009.
For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45 percent from $121.8 million for the same partner companies for the same period of 2009. (Note: Revenue for Safeguard's equity method and cost method partner companies is reported on a one-quarter lag.)
As a result of this growth, Safeguard has increased its 2010 aggregate partner company revenue guidance to a range of $325 million to $350 million, up from a range of $300 million to $325 million.
Peter J. Boni, Safeguard Scientifics' President and CEO, highlighted that there is continued growth and maturation at Safeguard's life sciences and technology partner companies. In addition, over the course of the next year, we anticipate several potential exit opportunities involving some of our more mature partner companies.
More news can be found in our full quarterly results press release. You can also listen to our LIVE conference call and webcast at 9 a.m. EDT this morning.
If you have any questions, please feel free to contact me. Thanks, and have a great day.
For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45 percent from $121.8 million for the same partner companies for the same period of 2009. (Note: Revenue for Safeguard's equity method and cost method partner companies is reported on a one-quarter lag.)
As a result of this growth, Safeguard has increased its 2010 aggregate partner company revenue guidance to a range of $325 million to $350 million, up from a range of $300 million to $325 million.
Peter J. Boni, Safeguard Scientifics' President and CEO, highlighted that there is continued growth and maturation at Safeguard's life sciences and technology partner companies. In addition, over the course of the next year, we anticipate several potential exit opportunities involving some of our more mature partner companies.
More news can be found in our full quarterly results press release. You can also listen to our LIVE conference call and webcast at 9 a.m. EDT this morning.
If you have any questions, please feel free to contact me. Thanks, and have a great day.
Tuesday, July 27, 2010
Reminder: Safeguard Scientifics' Quarterly Results Call Tomorrow Morning
REMINDER: Second quarter results to be issued tomorrow. Here's the link: www.safeguard.com/results
Monday, July 26, 2010
Safeguard Scientifics to Announce Second Quarter 2010 Financial Results this Thursday
Thought I'd mention that Safeguard Scientifics is releasing its financial results for the second quarter ended June 30, 2010 prior to market open this Thursday, July 29. At 9 a.m. EDT that morning, Safeguard is hosting a conference call on which Peter J. Boni, our President and CEO, and Stephen T. Zarrilli, our CFO, will be providing a company update. Here's the link to listen to our live webcast: www.safeguard.com/results.
If you would prefer, there is also a conference call dial-in number: 877-640-9871 (International: +914-495-8549). Conference ID #: 85836033.
We hope that you can listen in to hear about the progress we're making at Safeguard Scientifics and our partner companies.
If you would prefer, there is also a conference call dial-in number: 877-640-9871 (International: +914-495-8549). Conference ID #: 85836033.
We hope that you can listen in to hear about the progress we're making at Safeguard Scientifics and our partner companies.
Friday, July 23, 2010
Swap Movement Comes of Age
First there was e-commerce, then online auctions, and then online classifieds for buying and selling used items. Now there's an increasing demand for online trading, driven in no small part by an economy where consumers are spending less, searching for great deals, and wanting to be more environmentally friendly. Swapping is only the next logical step in Internet commerce.
Capitalizing on the "Swap Movement" that is taking on the nation and the world, Swaptree.com announced this week that it acquired the domain Swap.com. The company's goal is to build the world's biggest swapping site, expand its swapping capabilities to more categories beyond digital media, and to provide users with a "one-stop swapping" website where users have the ability to swap just about anything they want.
Swap.com will enable the company to attract a wider array of members, which means more items available for swapping. Stay tuned for more details as the company plans to debut its new, branded website over the next few months.
Capitalizing on the "Swap Movement" that is taking on the nation and the world, Swaptree.com announced this week that it acquired the domain Swap.com. The company's goal is to build the world's biggest swapping site, expand its swapping capabilities to more categories beyond digital media, and to provide users with a "one-stop swapping" website where users have the ability to swap just about anything they want.
Swap.com will enable the company to attract a wider array of members, which means more items available for swapping. Stay tuned for more details as the company plans to debut its new, branded website over the next few months.
Wednesday, July 14, 2010
Monday, July 12, 2010
Bloomberg Businessweek says Avid likely to Beat GE, Bayer to Market
On the eve of the International Conference on Alzheimer's Disease (ICAD), Bloomberg Businessweek's Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard Scientifics partner company, " ... will likely beat General Electric Co. and Bayer AG to the market with the first imaging test to pinpoint Alzheimer's early on in the disease."
That's high praise from one of the world's most respected business publications.
"Avid has completed the final tests needed for U.S. approval [of its imaging agent to identify proteins in the brain, called beta amyloid, that are markers for Alzheimer's], and aims to submit its results this year."
Both GE and Bayer have their own imaging agents in earlier testing stages and are certainly large and formidable competitors.
But as the authors point out, Avid has strong partners of its own. The Company has ties to the medical unit of Siemens AG of Munich, Germany, which makes the dye for Avid. Chief Executive Officer Daniel M. Skovronsky, M.D., Ph.D. has said the company will continue to rely on strong partners and backers and "as a growing biotech company, [will] always [have a] need for financing. We are always thinking about where our next dollar is going to come from."
The U.S. National Institutes of Health estimates as many as 5.1 million Americans have this debilitating disease for which there is no cure. Harry Glorikian of Scientia Advisors, an industry consulting firm, believes the market for imaging agents could consequently reach $3 billion.
While those are market characteristics that are bound to invite competition, they are also characteristics that create tremendous opportunity. Here's the complete article.
That's high praise from one of the world's most respected business publications.
"Avid has completed the final tests needed for U.S. approval [of its imaging agent to identify proteins in the brain, called beta amyloid, that are markers for Alzheimer's], and aims to submit its results this year."
Both GE and Bayer have their own imaging agents in earlier testing stages and are certainly large and formidable competitors.
But as the authors point out, Avid has strong partners of its own. The Company has ties to the medical unit of Siemens AG of Munich, Germany, which makes the dye for Avid. Chief Executive Officer Daniel M. Skovronsky, M.D., Ph.D. has said the company will continue to rely on strong partners and backers and "as a growing biotech company, [will] always [have a] need for financing. We are always thinking about where our next dollar is going to come from."
The U.S. National Institutes of Health estimates as many as 5.1 million Americans have this debilitating disease for which there is no cure. Harry Glorikian of Scientia Advisors, an industry consulting firm, believes the market for imaging agents could consequently reach $3 billion.
While those are market characteristics that are bound to invite competition, they are also characteristics that create tremendous opportunity. Here's the complete article.
Subscribe to:
Posts (Atom)
Posts
